Testosterone: no ester

Testosterone Suspension

Testosterone suspension is the app's name for an injectable testosterone preparation with no ester; the app's 39 hour half-life matches a median measured in 20 horses, and no human trial of it turned up in the records.

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Testosterone Suspension after one dose: 50% at ~39 h, 25% at 78 h, 12.5% at 117 h.

Drawn from the half-life in the app's model, ~39 h. The model's figures

Testosterone suspension is the app's name for an injectable testosterone preparation with no ester attached, which the app describes as unmodified testosterone in aqueous or oil suspension whose microcrystalline particles create a depot effect with variable absorption.

An expert opinion document by Kalra and colleagues (International Journal of Endocrinology, 2023) lists an “aqueous suspension of testosterone” among injectable testosterone preparations, and Kalra and colleagues (Journal of Mid-Life Health, 2022) list “testosterone suspension” in a table of preparations in the Indian market.1,2 A 2021 review by McCullough and colleagues (Reviews in Endocrine and Metabolic Disorders) lists “Testosterone Suspension” among injectable anabolic androgenic steroids, with a typical weekly dose of 150–700 mg.3

The only measured pharmacokinetic data located under the preparation's name come from horses: Moeller and colleagues at the University of California, Davis (Journal of Veterinary Pharmacology and Therapeutics, 2011) gave an aqueous testosterone suspension intramuscularly to 20 Thoroughbred horses and reported a median terminal half-life of 39 hours.4 Searches of PubMed and Europe PMC on 16 November 2026 for the preparation's name returned no human trial or human pharmacokinetic study of it among the records read. The only human treatment reports located, by Freed in 1946 and by Ragab and El-Itribi in 1949 (whose title names ten cases of male hypogonadism), were available as titles and citations only, so their results are not known.9,10

The sources read use different names: “aqueous suspension of testosterone”, “testosterone suspension” and “Testosterone Suspension” in the human documents, “aqueous testosterone suspension” in the 2011 horse study and “Testosterone Suspension 100” in the two later horse studies. None of them states that these are one product, and none describes particle size or a depot effect for the preparation.

The figures row above is the app's own, and the evidence badge is the app's grade, not a conclusion of the sources. The 39 hour half-life matches a horse median, the human documents list 25–50 mg every 1–2 weeks and 150–700 mg a week, and none of the sources read states the app's 100% bioavailability, 1 hour time to peak or 25–100 mg typical dose.1,2,3

2

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~39 h
Bioavailability
100%
Typical dose
25–100 mg
Route
IM
Time to peak
~1 h

The app lists a half-life of about 39 hours (1.6 days), a bioavailability of 100%, a time to peak of about 1 hour and a duration of 48 hours for testosterone suspension.

The 39 hour figure equals the median terminal half-life that Moeller and colleagues measured in 20 horses, which is a measurement in animals and not in people.4 None of the sources read states a half-life in people, a bioavailability, a time to peak or a duration of activity for the preparation.

Table 2.1Half-life and pharmacokinetics3 rows
MeasureValueSource and setting
Median terminal half-life39 hMoeller and colleagues, 2011: aqueous testosterone suspension given intramuscularly in the neck of 20 Thoroughbred horses4
Absorption in horsesAn initial, rapid absorption phase followed by a much more variable secondary absorption phaseMoeller and colleagues, 2011, same 20 horses4
Detection time after Testosterone Suspension 100Average 14 days in plasma or urine, using the proposed plasma threshold of 100 pg/mL of free testosterone and the existing international urine threshold of 20 ng/mL of free and conjugated testosterone; maximum 18 days in plasma and 20 days in urineHo and colleagues, 2015: 6 geldings; the dose is not given in the record read5

The app's 1 hour time to peak and 48 hour duration are not stated in any of the sources read. In the horse study the disposition had “an initial, rapid absorption phase followed by a much more variable secondary absorption phase”, the human documents list intervals of 1 to 2 weeks, and the geldings' detection times were 14 days on average and up to 20 days.4,1,5

The adjustable chart below is an illustration of the app's figures, a half-life of 39 hours and a time to peak of 1 hour, and not a measured human profile; its 7 and 14 day intervals match the intervals listed in the 2023 expert opinion table, and its dose range is the chart's own, not taken from a source.1

Level over 4 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: every 7 days1, every 14 days1.

An illustration from a pharmacokinetic model using a half-life of 39 hours. It is not a measured level or a suggested dose.

3

Human studies and clinical documents

Three published documents in the sources read state a dose or a use for the preparation in people, and none of the three is a trial.1,2,3

Table 3.1Human studies and clinical documents3 rows
Study and yearDesignPeopleDose and lengthMain result
Kalra and colleagues, 20231Expert opinion document built from five advisory board meetings and a PubMed literature review; not a trialNo participants; the document concerns men with male hypogonadism in IndiaAqueous suspension of testosterone, 25–50 mg every 1–2 weeks; no length givenListed under “For quicker benefits”, with “Increased frequency of administration” as the point to consider
Kalra and colleagues, 20222Journal article on counselling for testosterone therapy; not a trialNo participantsTestosterone suspension, 25-50 mg q7-14 days; no length givenListed in a table of preparations in the Indian market; another table lists “IM aqueous suspension; gel” for “Need for immediate resolution of symptoms”
McCullough and colleagues, 20213Review of anabolic androgenic steroids; not a trialNo participants; the review concerns anabolic androgenic steroid use, “mostly for appearance and performance enhancing reasons”Testosterone Suspension, 150–700 mg typical weekly dose; no length givenListed among injectable anabolic androgenic steroids in a table of “typical doses used”

Deeper analysis: the 2023 Indian expert opinion document

Kalra and colleagues convened five virtual advisory board meetings of specialists from across India and formulated key opinions from the group discussions into a consensus document on male hypogonadism.1 Beside its table, the text states that “if the patient accepts injectable testosterone as a therapy, one may start with short-acting aqueous formulations given once a week to once a fortnight”, which “are associated with the rapid achievement of optimal serum testosterone and also help in the rapid resolution of symptoms”.1 This is an expert statement about short-acting aqueous formulations in general, in men with hypogonadism, and the sentence carries no citation of its own in the text read.1

Abbott Healthcare sponsored the advisory board meetings, the authors state that the views are their own and not the sponsor's, medical writing support came from Bioquest Solutions, four of the 12 authors disclose speaker, consulting or advisory board ties that include Abbott, and the document lists no limitations of its method.1

Deeper analysis: the 2022 counselling article and the 2021 review

Kalra S is first author of both the 2022 article and the 2023 expert opinion document, so the 25–50 mg every 1–2 weeks row comes twice from one lead author and is not an independent replication. The 2022 article states “There are no conflicts of interest.”2 In its Table 4, “IM aqueous suspension; gel” is listed for “Efficacy: Need for immediate resolution of symptoms”, while “Safety: Fear of side effects” and “Tolerability: Uncertainty about long term tolerance” list “Capsules, gel”, and “Stability in testosterone levels” lists “IM testosterone undecanoate”.2 The 2023 document adds that “it is advisable to begin with gel, oral preparation, or aqueous injection while initiating therapy”, and its Table 5 states that “patients can later be shifted to long-acting preparations if they desire, once safety and tolerability have been demonstrated with shorter-acting testosterone”.1

McCullough and colleagues, of Liverpool John Moores University and collaborating groups, review anabolic androgenic steroid use, which they describe as “mostly for appearance and performance enhancing reasons”, and their table of “typical doses used” gives 150–700 mg a week for Testosterone Suspension, a different population and dose range from the Indian clinical documents.3 The review states that anabolic androgenic steroid use “markedly decreases high-density lipoprotein cholesterol (HDL-C) and increases low-density lipoprotein cholesterol (LDL-C)” and that chronic use “appears to cause higher fasting insulin levels and impaired glucose tolerance”; these are findings for the class and not measurements for the suspension.3

Deeper analysis: the 2011 horse study

Moeller and colleagues, of the Equine Analytical Chemistry Laboratory at the University of California, Davis, gave an aqueous testosterone suspension intramuscularly in the neck of 20 Thoroughbred horses so that withdrawal guidelines could be set, and report “an initial, rapid absorption phase followed by a much more variable secondary absorption phase” and a median terminal half-life of 39 h.4 A second aim was to compare testosterone concentrations from two laboratories, and a coefficient of variation of 16.5% was reported as good agreement.4 The authors conclude that “a withdrawal period of 30 days for aqueous testosterone administered IM is recommended”.4 The PubMed record states no funder, no limitations, no dose and no range around the median, and every result in it is from horses.4

Later gelding studies from Hong Kong

Ho and colleagues of the Hong Kong Jockey Club Racing Laboratory (Drug Testing and Analysis, 2015) built a method for free testosterone in gelding plasma, found a mean plasma testosterone of 14.7 ± 6.8 pg/mL in 152 post-race plasma samples, proposed a 100 pg/mL plasma threshold, and gave Testosterone Suspension 100 to six geldings; the detection times are in the table above.5 They state that the proposed threshold was adopted by the International Federation of Horseracing Authorities in October 2013.5

Wong and colleagues of the same laboratory (Drug Testing and Analysis, 2017) treated a gelding in 2009 with a single 500 mg intramuscular dose of Testosterone Suspension 100, and in administration trials on six castrated horses detected and confirmed low levels of boldenone, nandrolone, 5(10)-estrene-3β,17α-diol and 4-estrene-3,17-dione in early urine samples from all six.6 In vitro incubations with horse tissues “failed to provide evidence that these four substances are minor metabolites of testosterone”.6 A trial with 13C-labelled testosterone added to Testosterone Suspension 100 (500 mg, 1:1 ratio) then detected labelled boldenone, nandrolone and 4-estrene-3,17-dione but not 5(10)-estrene-3β,17α-diol, which the authors call “the first unequivocal evidence of boldenone, nandrolone and 4-estrene-3,17-dione being metabolites of testosterone in geldings”, and they advise caution when interpreting findings of boldenone, nandrolone and/or 4-estrene-3,17-dione together with a relatively high level of testosterone in gelding urine.6

5

Regulatory and anti-doping status

The WADA Prohibited List 2026, in effect from 1 January 2026, lists testosterone among the anabolic androgenic steroids in S1.1, “when administered exogenously”, in a class prohibited at all times, in and out of competition.7 The list entry is the substance testosterone, and the list text read names no formulation of it.7

Under 21 CFR 1308.13, Schedule III paragraph (f) opens “Unless specifically excepted or unless listed in another schedule, any substance meeting the definition of anabolic steroid as set forth in § 1300.01 of this chapter, including any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers”, and item (84) is testosterone.8 The regulation text does not name testosterone suspension as a product.8

6

What is not known

The sources read give no half-life, bioavailability, time to peak or duration of activity for testosterone suspension in people, and the app's half-life matches a horse measurement.

None of the sources read reports adverse events or marker results after the preparation itself in people; the McCullough review reports lipid and glucose findings for anabolic androgenic steroid use as a class.

Two older records have titles that name aqueous testosterone suspensions, Freed in the Journal of Clinical Endocrinology and Metabolism in 1946 and Ragab and El-Itribi in the Journal of the Egyptian Medical Association in 1949 (a title that names ten cases of male hypogonadism and impotence), and the records read hold a title and a citation with no further text, so no result from either is reported here.9,10

What is testosterone suspension?

Testosterone suspension is the app's name for an injectable testosterone preparation with no ester attached, described as unmodified testosterone in aqueous or oil suspension. A 2023 Indian expert opinion document lists an “aqueous suspension of testosterone” among injectable testosterone preparations.1

What is the half-life of testosterone suspension?

The app uses a half-life of about 39 hours (1.6 days) for testosterone suspension. The same figure is the median terminal half-life that Moeller and colleagues measured in 20 Thoroughbred horses in 2011, and the sources read give no half-life measured in people.4

How long does testosterone suspension take to peak?

The app uses a time to peak of about 1 hour for testosterone suspension, and none of the sources read states a time to peak for it.

Has testosterone suspension been studied in humans?

No human trial or human pharmacokinetic study of testosterone suspension turned up in searches of PubMed and Europe PMC on 16 November 2026 among the records read. A 2023 Indian expert opinion document and a 2022 article list it among injectable preparations, and neither is a trial.1,2 Two records from 1946 and 1949 have titles about aqueous testosterone suspensions and were available as titles only.9,10

What doses of testosterone suspension are reported?

The 2023 expert opinion table lists an aqueous suspension of testosterone at 25–50 mg every 1–2 weeks, and the 2022 article, which has the same first author, lists 25-50 mg q7-14 days.1,2 McCullough and colleagues list a typical weekly dose of 150–700 mg in a table of doses used in anabolic androgenic steroid use, mostly for appearance and performance enhancing reasons.3 The app's own typical dose is 25–100 mg, which none of the sources read states.

Is testosterone suspension banned by WADA?

The WADA Prohibited List 2026 names testosterone among the anabolic androgenic steroids in S1.1, prohibited at all times, in and out of competition, and the entry is the substance testosterone.7

Is testosterone suspension a controlled substance in the US?

The only US listing in the sources read is for the substance testosterone: item (84) among the Schedule III anabolic steroids in 21 CFR 1308.13, a paragraph that covers “any material, compound, mixture or preparation containing any quantity” of the listed substances, “unless specifically excepted or unless listed in another schedule”, and the regulation text does not name testosterone suspension.8

9

References

  1. Kalra S, Jacob J, Unnikrishnan AG, et al. Expert Opinion on the Diagnosis and Management of Male Hypogonadism in India. Int J Endocrinol 2023. PMC9977550
  2. Kalra S, Joshi A, Dhingra A, et al. Counselling for Testosterone Therapy in Mid Life Men. J Midlife Health 2022. PMC9583362
  3. McCullough D, Webb R, Enright KJ, et al. How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health. Rev Endocr Metab Disord 2021. PMC8087567
  4. Moeller BC, Sams RA, Guinjab-Cagmat J, et al. An interlaboratory study of the pharmacokinetics of testosterone following intramuscular administration to Thoroughbred horses. J Vet Pharmacol Ther 2011. PMID 21366623
  5. Ho EN, Kwok WH, Leung DK, et al. Control of the misuse of testosterone in castrated horses based on an international threshold in plasma. Drug Test Anal 2015. PMID 24889217
  6. Wong JKY, Leung DKK, Curl P, et al. Evidence of boldenone, nandrolone, 5(10)-estrene-3β-17α-diol and 4-estrene-3,17-dione as minor metabolites of testosterone in equine. Drug Test Anal 2017. PMID 28322013
  7. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA 2026. WADA Prohibited List 2026
  8. US Drug Enforcement Administration. 21 CFR 1308.13 Schedule III. Code of Federal Regulations, eCFR 2026. eCFR 21 CFR 1308.13
  9. Freed SC. Therapeutic use of testosterone in aqueous suspension. J Clin Endocrinol Metab 1946. PMID 20996897
  10. Ragab AF, El-Itribi A. Perandren therapy with tablet implants and crystals in aqueous suspension in ten cases of male hypogonadism and impotence. J Egypt Med Assoc 1949. PMID 18128633